EA201070598A1 - Терапевтическое применение соединений, обладающих комбинированной активностью в отношении sert, 5-htи 5-ht - Google Patents

Терапевтическое применение соединений, обладающих комбинированной активностью в отношении sert, 5-htи 5-ht

Info

Publication number
EA201070598A1
EA201070598A1 EA201070598A EA201070598A EA201070598A1 EA 201070598 A1 EA201070598 A1 EA 201070598A1 EA 201070598 A EA201070598 A EA 201070598A EA 201070598 A EA201070598 A EA 201070598A EA 201070598 A1 EA201070598 A1 EA 201070598A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hti
sert
owning
compounds
respect
Prior art date
Application number
EA201070598A
Other languages
English (en)
Other versions
EA027783B1 (ru
Inventor
Николас Мур
Марианне Драгхеим
Анеил Батра
Цзинь Чон
Original Assignee
Х. Лундбекк А/С
Такеда Фармасьютикалз Норт Америка, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201070598(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Х. Лундбекк А/С, Такеда Фармасьютикалз Норт Америка, Инк. filed Critical Х. Лундбекк А/С
Publication of EA201070598A1 publication Critical patent/EA201070598A1/ru
Publication of EA027783B1 publication Critical patent/EA027783B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Представлены новые виды фармацевтического применения 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина и его фармацевтически приемлемых солей.
EA201070598A 2007-11-13 2008-11-12 Способ лечения бессонницы EA027783B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200701607 2007-11-13
DKPA200701788 2007-12-14
DKPA200801300 2008-09-17
PCT/DK2008/050271 WO2009062517A1 (en) 2007-11-13 2008-11-12 Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (2)

Publication Number Publication Date
EA201070598A1 true EA201070598A1 (ru) 2010-10-29
EA027783B1 EA027783B1 (ru) 2017-09-29

Family

ID=40170671

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070598A EA027783B1 (ru) 2007-11-13 2008-11-12 Способ лечения бессонницы

Country Status (30)

Country Link
US (5) US9278096B2 (ru)
EP (3) EP2219647B2 (ru)
JP (2) JP5603244B2 (ru)
KR (1) KR101536023B1 (ru)
CN (1) CN102014908A (ru)
AR (1) AR069260A1 (ru)
AT (1) ATE537829T1 (ru)
AU (1) AU2008323390B2 (ru)
BR (1) BRPI0820474B8 (ru)
CA (1) CA2705163C (ru)
CL (1) CL2008003363A1 (ru)
CO (1) CO6270322A2 (ru)
CY (2) CY1112646T1 (ru)
DK (2) DK2431039T3 (ru)
EA (1) EA027783B1 (ru)
ES (2) ES2379419T5 (ru)
HR (2) HRP20120144T4 (ru)
HU (1) HUE029588T2 (ru)
IL (1) IL205466A (ru)
LT (1) LT2431039T (ru)
MX (1) MX2010004688A (ru)
NZ (1) NZ585247A (ru)
PL (2) PL2431039T3 (ru)
PT (2) PT2219647E (ru)
RS (2) RS52256B2 (ru)
SG (1) SG10201405001XA (ru)
SI (2) SI2219647T2 (ru)
TW (1) TW200932233A (ru)
WO (1) WO2009062517A1 (ru)
ZA (1) ZA201003350B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
PL2470166T3 (pl) * 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
HUE036637T2 (hu) * 2011-01-27 2018-07-30 Neuren Pharmaceuticals Ltd Autizmus spektrumbetegségek kezelése glicil-L-2-metilprolil-L-glutaminsavval
WO2013012038A1 (ja) 2011-07-21 2013-01-24 学校法人名城大学 うつ病決定方法、セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
MX362886B (es) * 2012-12-13 2019-02-22 H Lundbeck As Composición sinérgica que comprende vortioxetina y donepezilo para incrementar los niveles de acetilcolina en el cerebro, y el uso de la misma en el tratamiento de una disfunción cognitiva.
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
WO2014191548A1 (en) * 2013-05-31 2014-12-04 Lek Pharmaceuticals D.D. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CA2933733A1 (en) * 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CA2992161A1 (en) * 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
JP2019524682A (ja) 2016-07-01 2019-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗うつ作用の速い発現のためのボルチオキセチン投与計画
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (ru) 2001-10-04 2008-02-11 Х. Луннбек А/С производные фенилпиперазина как ингибиторы обратного захвата серотонинА
ES2280595T3 (es) * 2001-12-20 2007-09-16 H. Lundbeck A/S Derivados de ariloxifenilo y arilsulfanilfenilo.
ATE406894T1 (de) 2003-04-04 2008-09-15 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
US20060019938A1 (en) 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
WO2007144005A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S 1- [2- (2, 4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
PL2470166T3 (pl) 2009-08-24 2013-11-29 H Lundbeck As Nowe kompozycje 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny

Also Published As

Publication number Publication date
EP2431039A1 (en) 2012-03-21
CO6270322A2 (es) 2011-04-20
PT2431039T (pt) 2016-09-29
EP2219647B1 (en) 2011-12-21
US20110201617A1 (en) 2011-08-18
HRP20120144T1 (en) 2012-04-30
IL205466A (en) 2014-06-30
HRP20161121T1 (hr) 2017-01-27
SI2219647T1 (sl) 2012-06-29
WO2009062517A1 (en) 2009-05-22
ES2591110T3 (es) 2016-11-24
AU2008323390B2 (en) 2013-10-24
CY1117978T1 (el) 2017-05-17
RS55147B1 (sr) 2016-12-30
ZA201003350B (en) 2011-08-31
US20240082239A1 (en) 2024-03-14
EP2219647B2 (en) 2020-07-29
NZ585247A (en) 2012-03-30
US9278096B2 (en) 2016-03-08
BRPI0820474B1 (pt) 2020-08-04
BRPI0820474B8 (pt) 2021-05-25
DK2431039T3 (en) 2016-09-26
CN102014908A (zh) 2011-04-13
SG10201405001XA (en) 2014-10-30
HRP20120144T4 (hr) 2020-11-13
JP2014193891A (ja) 2014-10-09
RS52256B (en) 2012-10-31
PL2431039T3 (pl) 2016-12-30
DK2219647T4 (da) 2020-09-28
US11628166B2 (en) 2023-04-18
CA2705163A1 (en) 2009-05-22
EP2431039B1 (en) 2016-07-20
PT2219647E (pt) 2012-03-16
IL205466A0 (en) 2010-12-30
KR20100099115A (ko) 2010-09-10
AU2008323390A1 (en) 2009-05-22
US9744166B2 (en) 2017-08-29
ATE537829T1 (de) 2012-01-15
AR069260A1 (es) 2010-01-06
CY1112646T1 (el) 2016-02-10
EA027783B1 (ru) 2017-09-29
LT2431039T (lt) 2016-10-10
US20160228430A1 (en) 2016-08-11
CA2705163C (en) 2013-02-12
JP5841636B2 (ja) 2016-01-13
JP2011503125A (ja) 2011-01-27
MX2010004688A (es) 2010-09-09
PL2219647T3 (pl) 2012-07-31
US20180161321A1 (en) 2018-06-14
KR101536023B9 (ko) 2023-03-29
SI2219647T2 (sl) 2020-11-30
CL2008003363A1 (es) 2009-06-05
RS52256B2 (sr) 2020-11-30
DK2219647T3 (da) 2012-03-19
ES2379419T3 (es) 2012-04-25
EP2219647A1 (en) 2010-08-25
SI2431039T1 (sl) 2017-01-31
JP5603244B2 (ja) 2014-10-08
KR101536023B1 (ko) 2015-07-10
EP3115050A1 (en) 2017-01-11
HUE029588T2 (en) 2017-03-28
BRPI0820474A2 (pt) 2017-05-23
ES2379419T5 (es) 2021-05-04
US20210093631A1 (en) 2021-04-01
TW200932233A (en) 2009-08-01

Similar Documents

Publication Publication Date Title
EA201070598A1 (ru) Терапевтическое применение соединений, обладающих комбинированной активностью в отношении sert, 5-htи 5-ht
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
UY30500A1 (es) Compuestos de azabencimidazolilo
EA201290255A1 (ru) Способы и композиции для лечения рака
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
UY31189A1 (es) Compuestos heterocíclicos
PE20140099A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA201101672A1 (ru) Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
RS52205B (en) 1- [2- (2,4-dimethylphenylsulfanyl) -phenyl] piperazine as a compound with the combined re-uptake activity of SEROTONIN, 5-HT3 and 5-HT1A, for the treatment of cognitive impairment
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
EA201071144A1 (ru) Гетероциклические производные
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
EA201290116A1 (ru) Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
UA112055C2 (uk) Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
SE0401342D0 (sv) Therapeutic compounds
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
EA200970871A1 (ru) Новое терапевтическое применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM